The sustainable supply of drugs for antimicrobial resistance (AMR) is needed on a global scale. However, this will require both pull incentive models for reimbursement and high technology for producing molecules with complex structures, while also ensuring compliance with Good Manufacturing Practice (GMP) standards.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?